The LILACS trial (Low-dose interleukin-2 in Patients with stable ischemic heart disease and acute coronary syndrome) explored the potential of Treg expansion in patients with acute coronary syndrome, in pursuit of therapeutically targeting Tregs in humans. Here, IL2 is linked to acute coronary syndrome.